Evidence map›Paper›PMID 24651453›Full record

ArticleMolecular cancer research : MCR2014

HD chromoendoscopy coupled with DNA mass spectrometry profiling identifies somatic mutations in microdissected human proximal aberrant crypt foci.

David A Drew, Thomas J Devers, Michael J O'Brien, Nicole A Horelik, Joel Levine, Daniel W Rosenberg

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

David A DrewAuthors' Affiliations: Center for Molecular Medicine; Colon Cancer Prevention Program, Neag Comprehensive Cancer Center, School of Medicine, University of Connecticut Health Center, Farmington, Connecticut; and.
Thomas J DeversDivision of Gastroenterology; Colon Cancer Prevention Program, Neag Comprehensive Cancer Center, School of Medicine, University of Connecticut Health Center, Farmington, Connecticut; and.
Michael J O'BrienDepartment of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts.
Nicole A HorelikAuthors' Affiliations: Center for Molecular Medicine; Colon Cancer Prevention Program, Neag Comprehensive Cancer Center, School of Medicine, University of Connecticut Health Center, Farmington, Connecticut; and.
Joel LevineDivision of Gastroenterology; Colon Cancer Prevention Program, Neag Comprehensive Cancer Center, School of Medicine, University of Connecticut Health Center, Farmington, Connecticut; and.
Daniel W RosenbergAuthors' Affiliations: Center for Molecular Medicine; Colon Cancer Prevention Program, Neag Comprehensive Cancer Center, School of Medicine, University of Connecticut Health Center, Farmington, Connecticut; and rosenberg@uchc.edu.
UConn Health · USBoston Medical Center · USCommunity Options (United States) · US

Funding

Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
Are ACF Surrogate Markers for Chemoprevention?R01CA159976 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ROSENBERG, DANIEL WILLIAM · 2012 to 2016
$1.9M
NCATS NIH HHS UL1 TR000142NCI NIH HHS 1R01CA159976NCI NIH HHS R01 CA159976
6 · The paper itself

Abstract

unlabelledDespite increased implementation of screening colonoscopy, interval cancers in the proximal colon remain a major public health concern. This fact underscores the limitations of current screening paradigms and the need for developing advanced endoscopic techniques. The density of aberrant crypt foci (ACF), the earliest identifiable mucosal abnormality, may serve as a surrogate marker for colon cancer risk, but has rarely been studied in the proximal colon. To this end, high-definition (HD) chromoendoscopy was conducted to define the relevance of ACF in the proximal colon. In addition, due to limited ACF size, the development of a combinatorial approach was required to maximize data acquisition obtained from individual biopsy samples. Proximal and distal ACF samples were characterized for a total of 105 mutations across 22 known tumor suppressor and proto-oncogenes using high-throughput Sequenom MassARRAY analysis. From this profiling, a discrete number of somatic mutations were identified, including APC(R876*) and FLT3(I836M), as well as a deletion within the EGFR gene. Combined, these data highlight the significance of ACF within the context of colon cancer pathogenesis, particularly in the proximal colon. IMPLICATIONS: The identification of cancer-related mutations in commonly overlooked mucosal lesions underscores the preventive benefit of implementing advanced endoscopic screening to larger patient populations, particularly in the proximal colon. Visual Overview: http://mcr.aacrjournals.org/content/early/2014/05/22/1541-7786.MCR-13-0624/F1.large.jpg. Mol Cancer Res; 12(6); 823-9. ©2014 AACR.

Indexed as

MutationAberrant Crypt FociColonoscopyColorectal NeoplasmsDNA, NeoplasmHumansImmunohistochemistryIntestinal MucosaMass SpectrometryMicrodissectionDNA, Neoplasm

Identifiers

PMID24651453
PMCPMC4058342
OpenAlexW2128610155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.